Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Diabetes and Osteoporosis Are Related: Prof. Okazaki
August 10, 2009
- Industry Must Give Clearer Explanations about Need for NHI Pricing System Reform: Mr Kinoshita
August 10, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 10, 2009
- Marketing Authorization Holders Must Maintain Close Communication with Suppliers
August 10, 2009
- Hisamitsu to Increase Overseas Sales to 15% of Total Sales
August 10, 2009
- OMT Creates First Targeted Immunoglobulin Knockout Rats
August 10, 2009
- Takeda to Promote Wyeths Seltouch from October
August 10, 2009
- Comprehensive Clinical Trial Program Proposed in NDAs for Oral Antidiabetics
August 10, 2009
- Daiichi Sankyo to Launch Effient in the US in August
August 10, 2009
- REGULATORY NEWS IN BRIEF
August 10, 2009
- Zeria to Acquire Tillotts
August 10, 2009
- Introduce Financial Incentives to Promote Use of Generics: Mr Sawai of JGA
August 10, 2009
- Erbitux Sales to Exceed 1 Bil. Euro Mark
August 10, 2009
- Combination Drugs Interfere with Promotion of Generics: JSHP
August 10, 2009
- No. 3 and No. 4 CSOs to Merge
August 10, 2009
- Establish Regional Networks to Promote Use of Generics: Mr Kinoshita
August 10, 2009
- BUSINESS NEWS IN BRIEF
August 10, 2009
- 8 Prefectures to Prepare Lists of Generics Stocked by Regional Pharmacies
August 10, 2009
- Eisai Licenses Drug-Eluting Bead Products from Biocompatibles
August 10, 2009
- JPMA to Propose Fee-for-Service for Clinical Trials
August 10, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…